Role of FOXP3 in Tumor Immunity

Xu Zhang

2009-01-01

Abstract:FOXP3,a member of the forkhead/winged-helix family,exerts its immunosupression effect by regulating the development,differentiation and maturation of CD4+ CD25+ regulatory T cells(Treg).Treg plays an important role in immune escape mechanism in oncology research.This article reviews the expression of FOXP3 in various types of tumors and its role in tumor immunology and immunotherapy.

What problem does this paper attempt to address?

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Xiaoxu Ge,Yamei Zhao,Chao Chen,Jian Wang,Lifeng Sun

DOI: https://doi.org/10.2147/OTT.S231052

IF: 4

2019-01-01

OncoTargets and Therapy

Abstract:Tumor-associated regulatory T cells (Tregs) are important effectors in the tumor microenvironment (TME), acting as accomplices in the promotion of tumor progression. Currently, the importance of removing the immunosuppressive activity in the TME has received its due attention, and Tregs have been focused on. The cytokine-receptor axes are among the essential signaling pathways in immunocytes, and tumor-associated Tregs are no exception. Therefore, manipulating cytokine-receptor pathways may be a promising effective strategy for treating various malignancies. Here, we summarize the classification, immunosuppressive mechanisms, existing immunotherapies, and potential biomarkers related to tumor-infiltrating Tregs to guide the development of effective cancer immunotherapies.
The Role of FOXP3 on Tumor Metastasis and Its Interaction with Traditional Chinese Medicine

Benxu Ma,Wenjun Miao,Jieqiong Xiao,Xinyi Chen,Jing Xu,Yinan Li

DOI: https://doi.org/10.3390/molecules27196706

IF: 4.6

2022-10-09

Molecules

Abstract:Forkhead box protein 3 (FOXP3) is an important transcription factor for regulatory T cells (Tregs) and plays an important role in their immunosuppressive function. In recent years, studies have found that FOXP3 is expressed in many kinds of tumors and plays different roles in tumors' biological behaviors, including tumor proliferation, metastasis, drug resistance, and prognosis. However, the effects of FOXP3 on tumor metastasis and its interaction with traditional Chinese medicine (TCM) remain unclear. Therefore, in this review, we focus on the effects of FOXP3 on tumor metastasis and its relationship with TCM, which can provide evidence for further research and therapy in clinical settings.

chemistry, multidisciplinary,biochemistry & molecular biology
FOXP3: A Player of Immunogenetic Architecture in Lung Cancer

Iwona Ziółkowska-Suchanek,Magdalena Żurawek

DOI: https://doi.org/10.3390/genes15040493

IF: 4.141

2024-04-16

Genes

Abstract:The transcription factor forkhead box protein 3 (FOXP3) is considered to be a prominent component of the immune system expressed in regulatory T cells (Tregs). Tregs are immunosuppressive cells that regulate immune homeostasis and self-tolerance. FOXP3 was originally thought to be a Tregs-specific molecule, but recent studies have pinpointed that FOXP3 is expressed in a diversity of benign tumors and carcinomas. The vast majority of the data have shown that FOXP3 is correlated with an unfavorable prognosis, although there are some reports indicating the opposite function of this molecule. Here, we review recent progress in understanding the FOXP3 role in the immunogenetic architecture of lung cancer, which is the leading cause of cancer-related death. We discuss the prognostic significance of tumor FOXP3 expression, tumor-infiltrating FOXP3-lymphocytes, tumor FOXP3 in tumor microenvironments and the potential of FOXP3-targeted therapy.

genetics & heredity
FOXN Transcription Factors: Regulation and Significant Role in Cancer

Jieun Song,Longshan Li,Fang Yang,Yue Lin,Licia N.Y. Wu,Wei Wan,Gen Wei,Fuzhou Hua,Jun Ying

DOI: https://doi.org/10.1158/1535-7163.mct-23-0208

2023-01-01

Molecular Cancer Therapeutics

Abstract:A growing number of studies have demonstrated that cancer development is closely linked to abnormal gene expression, including alterations in the transcriptional activity of transcription factors. The Forkhead box class N (FOXN) proteins FOXN1–6 form a highly conserved class of transcription factors, which have been shown in recent years to be involved in the regulation of malignant progression in a variety of cancers. FOXNs mediate cell proliferation, cell-cycle progression, cell differentiation, metabolic homeostasis, embryonic development, DNA damage repair, tumor angiogenesis, and other critical biological processes. Therefore, transcriptional dysregulation of FOXNs can directly affect cellular physiology and promote cancer development. Numerous studies have demonstrated that the transcriptional activity of FOXNs is regulated by protein–protein interactions, microRNAs (miRNA), and posttranslational modifications (PTM). However, the mechanisms underlying the molecular regulation of FOXNs in cancer development are unclear. Here, we reviewed the molecular regulatory mechanisms of FOXNs expression and activity, their role in the malignant progression of tumors, and their value for clinical applications in cancer therapy. This review may help design experimental studies involving FOXN transcription factors, and enhance their therapeutic potential as antitumor targets.
The regulation of immune tolerance by FOXP3

Ling Lu,Joseph Barbi,Fan Pan

DOI: https://doi.org/10.1038/nri.2017.75

IF: 108.555

2017-07-31

Nature Reviews Immunology

Abstract:Key PointsForkhead box protein P3 (FOXP3) is a crucial regulator of regulatory T (Treg) cell gene expression that is responsible for much of the suppressive potential displayed by these cells.The regulation of FOXP3 expression in Treg cells occurs through the concerted action of transcription factors and extensive epigenetic control mechanisms; furthermore, post-translational modifications are also capable of modulating FOXP3 function.These several layers of FOXP3 control are responsive to positive and negative regulation by factors in the tissue environment, including cytokines, inflammatory mediators and metabolic factors.Modulating FOXP3 expression and Treg cell function by targeting newly discovered regulatory nodes may lead to the development of new immunotherapies for cancer and autoimmune diseases.

immunology
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.

T. Hummel,L. Wagner,C. Ahern,R. McGovern,M. Ames,R. Gilbertson,T. Horton,A. Ingle,B. Weigel,S. Blaney

DOI: https://doi.org/10.1200/JCO.2011.29.15_SUPPL.9579

IF: 45.3

2011-05-20

Journal of Clinical Oncology

Abstract:9579 Background: The looser chromatin structure seen following treatment with histone deacetylase (HDAC) inhibitors is hypothesized to render cells more sensitive to drugs targeting DNA. A phase I trial of vorinostat (VOR), an HDAC inhibitor, combined with temozolomide (TEM) was conducted to investigate the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of this combination. VOR pharmacokinetics (PK), serum MGMT promoter status, and histone acetylation in peripheral blood mononuclear cells were also assessed. METHODS VOR followed by TEM were orally administered, once daily, for 5 consecutive days every 28 days at 3 dose levels using the rolling 6 design. The respective dose levels for VOR and TEM were: (1) 230 mg/m2/day; 150 mg/m2/day, (2) 300 mg/m2/day; 150 mg/m2/day and (3) 300 mg/m2/day; 200 mg/m2/day. Studies of histone accumulation in peripheral blood mononuclear cells were performed on day 1 at 0, 6, and 24 h after vorinostat dosing. Vorinistat pharmacokinetics (PK) and serum MGMT promoter status were also assessed. RESULTS Nineteen eligible patients, 12 males, median age 8 yrs (range, 2-20 ) with high grade glioma [n=7], ependymomas [n=4], medulloblastoma [n=2], PNET [n=2], ATRT [n=2], carcinoma [n=1], and ganglioglioma [n=1] were enrolled. Seventeen patients were fully evaluable for toxicity. There were no DLTs observed at dose level 1 (n=6) or 2 (n=6). DLT (myelosuppression) occurred in 2 patients at dose level 3: thrombocytopenia [n=2] and neutropenia [n=1]. Non-dose-limiting grade 3 or 4 toxicities related to protocol therapy were hematologic and included neutropenia [n=8], lymphopenia [n=7], thrombocytopenia [n=6], anemia [n=1] and leucopenia [n=6]. No grade 5 drug-related serious adverse events were observed. Results of PK and correlative biology studies will be presented. CONCLUSIONS Five-day courses of VOR 300 mg/m2/day in combination with TEM 150 mg/m2/day are well tolerated in children with recurrent CNS malignancies.
The emerging role of transcription factor FOXP3 in thyroid cancer

Zhongqin Gong,Hao Jia,Lingbin Xue,Dongcai LI,Xianhai Zeng,Minghui Wei,Zhimin Liu,Michael C. F. Tong,George G. Chen

DOI: https://doi.org/10.1007/s11154-021-09684-8

2021-08-31

Reviews in Endocrine and Metabolic Disorders

Abstract:Transcription factor FOXP3 is a crucial regulator in the development and function of regulatory T cells (Treg) that are essential for immunological tolerance and homeostasis. Numerous studies have indicated the correlation of tumor infiltrating FOXP3+ Treg upregulation with poor prognostic parameters in thyroid cancer, including lymph node metastases, extrathyroidal extension, and multifocality. Most immune-checkpoint molecules are expressed in Treg. The blockage of such signals with checkpoint inhibitors has been approved for several solid tumors, but not yet for thyroid cancer. Thyroid abnormalities may be induced by checkpoint inhibitors. For example, hypothyroidism, thyrotoxicosis, painless thyroiditis, or even thyroid storm are more frequently associated with anti-PD-1 antibodies (pembrolizumab and nivolumab). Therefore, Targeting FOXP3+ Treg may have impacts on checkpoint molecules and the growth of thyroid cancer. Several factors may impact the role and stability of FOXP3, such as alternative RNA splicing, mutations, and post-translational modification. In addition, the role of FOXP3+ Treg in the tumor microenvironment is also affected by the complex regulatory network formed by FOXP3 and its transcriptional partners. Here we discussed how the expression and function of FOXP3 were regulated and how FOXP3 interacted with its targets in Treg, aiming to help the development of FOXP3 as a potential therapeutic target for thyroid cancer.

endocrinology & metabolism
Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapy Value of FOXP3

yiyang chen,Wanbang zhou,Yiju gong,Jikui liu,xi ou

DOI: https://doi.org/10.21203/rs.3.rs-1253670/v1

2022-01-01

Abstract:Abstract Background: Previous studies reported that FOXP3 is involved in the regulation of tumor microenvironment and the regulation of tumor local immunity. However, its mechanism has not been fully studied. This study aims to explore the potential relationship between FOXP3 and cancer immunotherapy in 33 human cancers.Method: The gene expression data and clinical characteristics of 33 cancers were retrieved from the Cancer Genome Atlas database. The immunotherapy cohort includes GSE157893, GSE67501, and IMvigor210, which come from a comprehensive gene expression database and are included in previously published studies. Analyze clinical parameters, including patient age, gender, and tumor stage to assess the prognostic value of FOXP3. At the same time, we conducted survival analysis and correlation analysis of tumor microenvironment. The correlation between FOXP3 and immunosuppressive agents and stimulants, as well as major histocompatibility complexes was also analyzed. Potential pathways related to FOXP3 signaling in cancer have also been explored. In addition, the correlation between FOXP3 and two immunotherapy biomarkers (tumor mutation burden and microsatellite instability) was studied. Finally, the immunotherapy response relationship between FOXP3 and the immunotherapy cohort was explored.Results: Among 33 cancer types, FOXP3 expression is different in different clinical groups (gender, age, and tumor stage) in certain cancers, and it also shows potential prognostic value in predicting patient survival. FOXP3 is correlated with immune cell infiltration, immunomodulators and immunotherapy markers. In addition, low FOXP3 expression is significantly associated with certain pathways. However, no significant correlation was observed between FOXP3 and immunotherapy response.Conclusion: This study explored the immunotherapy value of FOXP3 in 33 human cancers, and provided evidence and insights for the application of FOXP3 in tumor immunotherapy. However, considering the bioinformatics methods used in this study, the findings of the study are only preliminary, and more relevant experimental verifications are needed.
FOXP3+ regulatory T cells and the immune escape in solid tumours

Yiran Qiu,Shouyu Ke,Jieqiong Chen,Zhizhen Qin,Wenle Zhang,Yaqin Yuan,Dehua Meng,Gang Zhao,Kejin Wu,Bin Li,Dan Li

DOI: https://doi.org/10.3389/fimmu.2022.982986

IF: 7.3

2022-10-13

Frontiers in Immunology

Abstract:FOXP3+ regulatory T (Treg) cells play critical roles in establishing the immunosuppressive tumour microenvironment, which is achieved and dynamically maintained with the contribution of various stromal and immune cell subsets. However, the dynamics of non-lymphoid FOXP3+ Treg cells and the mutual regulation of Treg cells and other cell types in solid tumour microenvironment remains largely unclear. In this review, we summarize the latest findings on the dynamic connections and reciprocal regulations of non-lymphoid Treg cell subsets in accordance with well-established and new emerging hallmarks of cancer, especially on the immune escape of tumour cells in solid tumours. Our comprehension of the interplay between FOXP3+ Treg cells and key hallmarks of cancer may provide new insights into the development of next-generation engineered T cell-based immune treatments for solid tumours.

immunology
Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex.

Xiaoyan Ke,Jing Wang,Lijuan Li,Irene H Chen,Hong Wang,Xiao-Feng Yang

DOI: https://doi.org/10.2741/2986

IF: 3.1

2008-01-01

Frontiers in Bioscience-Landmark

Abstract:CD4+CD25(high)FOXP3+ regulatory T cells (Tregs) play an important role in the maintenance of immunological self-tolerance by suppressing autoimmune responses and anti-tumor immune responses. The current model suggests that epithelial tumor cells recruit Tregs to inhibit anti-tumor immunity in the tumor microenvironment, which thus limits the efficiency of antitumor immune responses and immunotherapy. However, recent findings on Tregs in lymphomas have complicated this working model. The biopsy specimens of some lymphomas have significantly higher percentages of Tregs than that in tumor-free lymph nodes and normal peripheral mononuclear cells. Higher Tregs numbers in these lymphomas predict improved survival and prognosis of patients. In this brief review, we summarize the progress in following topics: (1) Tregs; (2) Tregs and T cell co-stimulation; (3) Tregs in lymphomas; and (4) Tregs in other Tumors. Further characterization of Tregs in lymphomas and other tumors will provide insight on the differential regulation of Tregs' function and survival, and define the potentials of Tregs-based immunotherapeutics.
FOXP3+ Tregs: Heterogeneous Phenotypes and Conflicting Impacts on Survival Outcomes in Patients with Colorectal Cancer

Changhua Zhuo,Ye Xu,Mingang Ying,Qingguo Li,Liyong Huang,Dawei Li,Sanjun Cai,Bin Li

DOI: https://doi.org/10.1007/s12026-014-8616-y

2015-01-01

Immunologic Research

Abstract:The tumor microenvironment composites a mixture of immune lymphoid cells, myeloid cells, stromal cells with complex cytokines, as well as numerous lymphovascular vessels. Colorectal cancer (CRC) is a common malignancy and one of the leading causes of tumor-related death in the United States and worldwide. The immune status in the tumor microenvironment contributes to the survival of a patient with CRC. Regulatory T cells (Tregs) are considered a key factor in immune escape and immunotherapy failure among cancer patients. The transcription factor forkhead box P3 (FOXP3) is a crucial intracellular marker and also a key developmental and functional factor for CD4+CD25+ Tregs. Tregs are correlated with survival in various human neoplasms, and elevated proportions of Tregs are usually associated with unfavorable clinical outcomes. However, the role of Tregs in CRC remains controversial. High densities of tumor-infiltrating Tregs in CRC patients are reported to be correlated with worse or better outcomes. And Tregs may not be predictive of prognosis after resection of the primary tumor. The exact explanations for these discordant results remain unclear. The heterogeneous instincts of cell phenotype, gene expression, and functional activities of Tregs may partly contribute this contrasting result. Furthermore, the lack of a robust marker for identifying Tregs or due to the different techniques applied is also account. The Treg-specific demethylated region (TSDR) was recently reported to be a specific epigenetic marker for natural Tregs (nTregs), which can stably express FOXP3. The FOXP3 -TSDR demethylation assay may be an promising technique for CRC-related nTregs studies.
FOXP3 and Its Partners: Structural and Biochemical Insights into the Regulation of FOXP3 Activity

Zhaocai Zhou,Xiaomin Song,Bin Li,Mark I. Greene

DOI: https://doi.org/10.1007/s12026-008-8029-x

2008-01-01

Immunologic Research

Abstract:Forkhead box protein P3 (FOXP3) contributes to a unique transcriptional signature and serves as a functional marker of CD4+CD25+ natural regulatory T cells. Dysfunction of FOXP3 in human is associated with fatal autoimmune disease known as immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) or X-linked autoimmunity–allergic disregulation syndrome (XLAAD). FOXP3 also can act as a breast tumor suppressor of the v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog (avian)) (Her2/neu) gene. While the suppressive functions of FOXP3 in maintaining the immune balance between tolerance and autoimmunity are obvious, the underlying molecular mechanism remains almost entirely undefined. Recent studies indicate that FOXP3 may form a dynamic superamolecular complex with a variety of molecular partners including transcription factors and enzymatic proteins to regulate transcription. How the FOXP3 ensemble changes in response to T-cell receptor signals and/or proinflammatory signal remains unclear although work from this laboratory has revealed its complexity. Structural information on FOXP3 complex may offer novel functional insights, as well as facilitate the development of rational means to modulate regulatory T-cell function in various human diseases.
Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cells.

Guoping Deng,Yan Xiao,Zhaocai Zhou,Yasuhiro Nagai,Hongtao Zhang,Bin Li,Mark I Greene

DOI: https://doi.org/10.1016/j.yexmp.2012.09.013

IF: 4.401

2012-01-01

Experimental and Molecular Pathology

Abstract:Regulatory T (Treg) cells are essential in preventing the host from developing certain autoimmune diseases and limiting excessive immune responses against pathogens. The normal function of most Treg cells requires sustained expression of functional FOXP3, a member of the FOXP family transcription factors. FOXP3 is distinct from other subfamily members because of its unique proline rich amino (N)-terminal domain. Mutations in this region are occasionally identified in certain patients with X-linked autoimmunity-allergic dysregulation syndrome (XLAAD) and similar mutations also increase susceptibility of autoimmune diseases in rodent models. Previous analyses of the FOXP3 N-terminal domain revealed a role in nuclear import, interaction with other transcription factors, and as sites of specific post-translational modifications of FOXP3 that contribute to FOXP3 stability.
Abstract 4988: FOXP3, a Critical Mediator of Regulatory T-cell Function, is Expressed in Subsets of Myeloid Cells.

Sudheer Kumar Gara,Yanli Pang,Christine Hollander,Li Yang

DOI: https://doi.org/10.1158/1538-7445.am2013-4988

IF: 11.2

2013-01-01

Cancer Research

Abstract:Abstract Forkhead box P3 (FOXP3) is a well-known molecular marker for regulatory T cells (Tregs) and is considered as a master regulatory transcription factor for the development, maturation and function of Tregs. Mutations in FOXP3 lead to severe immune deficiencies and cancer in human and mice. Administration of Foxp3-expressing Tregs drastically reduced the disease severity in animal models of diabetes, asthma and multiple sclerosis giving rise to hope for therapeutic options. It is not clear whether cell types other than Treg express FOXP3. While investigating TGFβ-mediated signaling in the myeloid lineage, we discovered a subset of myeloid derived suppressor cells (Gr-1+CD11b+ cells or MDSCs) that express FOXP3. Indeed these cells were CD3 negative suggesting that they are not of T cell lineage. Upon further investigation, we observed that these FOXP3 expressing myeloid cells are present in different tissues of mouse. Moreover, we found that they are elevated under pathological conditions. We are currently identifying the molecular function and mechanisms of Foxp3 expression in the myeloid subsets. Our work will provide new insight into the FOXP3 research area beyond regulatory T cells, and might reveal its role in regulating the immunosuppressive activity of MDSCs. Citation Format: Sudheer Kumar Gara, Yanli Pang, Christine Hollander, Li Yang. FOXP3, a critical mediator of regulatory T-cell function, is expressed in subsets of myeloid cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4988. doi:10.1158/1538-7445.AM2013-4988
FOXP3 suppresses breast cancer metastasis through downregulation of CD44

Cun Zhang,Yujin Xu,Qiang Hao,Shuning Wang,Hong Li,Jialin Li,Yuan Gao,Meng Li,Weina Li,Xiaochang Xue,Shouzhen Wu,Yingqi Zhang,Wei Zhang

DOI: https://doi.org/10.1002/ijc.29482

2015-09-15

Abstract:Forkhead box protein 3 (FOXP3) plays an important role in breast cancer as an X-linked tumor suppressor gene. However, the biological functions and significance of FOXP3 in breast cancer metastasis remain unclear. Here, we find that, clinically, nuclear FOXP3 expression is inversely correlated with breast cancer metastasis. Moreover, we demonstrate that FOXP3 significantly inhibits adhesion, invasion and metastasis of breast cancer cells in vivo and in vitro. In addition, the adhesion molecule CD44 is found to be suppressed by FOXP3 through transcriptome sequence analysis (RNA-seq). A luciferase reporter assay, chromatin immunoprecipitation and electrophoretic mobility shift assay identify CD44 as a direct target of FOXP3. The expression of CD44 is downregulated by FOXP3 in breast cancer cells. Importantly, anti-CD44 antibody reverses the FOXP3 siRNA-induced effects on the breast cancer cells in vitro and FOXP3 expression level in the nucleus of breast cancer cells is inversely correlated with CD44 expression level in clinic breast cancer tissues. Taken together, the results from the present study suggest that FOXP3 is a suppressor of breast cancer metastasis. FOXP3 directly binds to the promoter of CD44 and inhibits its protein expression, thereby suppressing adhesion and invasion of human breast cancer cells. This finding highlights the therapeutic potential of FOXP3-CD44 signaling to inhibit breast cancer metastasis.
Advance in the Study of CD4~+CD25~+FOXP3~+ Regulatory T Cell in Tumor Immune Evasion

GAO Qiang,QIU Shuang-jian,FAN Jia

DOI: https://doi.org/10.3969/j.issn.1007-3639.2007.08.018

2007-01-01

Abstract:As a distinct T cell subset with acknowledged specific function and marker, CD4+CD25+FOXP3+ regulatory T cells are thought to dampen T-cell immunity and to be the main obstacle tempering antitumor immunotherapy. Accumulating evidence has confirmed an increased pool of regulatory T cells both in the peripheral blood and the tumor microenvironment of cancer patients, which are indicative of disease progression, response to therapy, invasive phenotype and prognosis. Therefore, manipulation of regulatory T cells—including depletion, blocking trafficking into tumors, or reducing their differentiation and suppressive mechanisms—and concomitant stimulation of effector T cells, systemically or locally in tumors, represent new strategies for cancer treatment.
What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?

Abdo Meyiah,Eyad Elkord

DOI: https://doi.org/10.1080/1744666x.2024.2334258

2024-03-27

Expert Review of Clinical Immunology

Abstract:Introduction Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TME) may influence clinical outcomes negatively or positively, and it could play dual roles in cancer, either by promoting or inhibiting tumor development and progression. Some studies reported that high levels of FoxP3 could be associated with tumor progression and worse prognosis, while others reported contradictory results.

immunology
FOXP3 is a HCC Suppressor Gene and Acts Through Regulating the TGF-β/Smad2/3 Signaling Pathway

Jie-Yi Shi,Li-Jie Ma,Ji-Wei Zhang,Meng Duan,Zhen-Bin Ding,Liu-Xiao Yang,Ya Cao,Jian Zhou,Jia Fan,Xiaoming Zhang,Ying-Jun Zhao,Xiao-Ying Wang,Qiang Gao

DOI: https://doi.org/10.1186/s12885-017-3633-6

IF: 4.638

2017-01-01

BMC Cancer

Abstract:Background: FOXP3 has been discovered to be expressed in tumor cells and participate in the regulation of tumor behavior. Herein, we investigated the clinical relevance and biological significance of FOXP3 expression in human hepatocellular carcinoma (HCC).Methods: Expression profile of FOXP3 was analyzed using real-time RT-PCR, western blotting and immunofluorescence on HCC cell lines, and immunostaing of a tissue microarray containing of 240 primary HCC samples. The potential regulatory roles of FOXP3 were dissected by an integrated approach, combining biochemical assays, analysis of patient survival, genetic manipulation of HCC cell lines, mouse xenograft tumor models and chromatin immunoprecipitation (ChIP) sequencing.Results: FOXP3 was constitutively expressed in HCC cells with the existence of splice variants (especially exon 3 and 4 deleted,Delta 3,4-FOXP3). High expression of FOXP3 significantly correlated with low serum a-fetoprotein (AFP) level, absence of vascular invasion and early TNM stage. Survival analyses revealed that increased FOXP3 expression was significantly associated with better survival and reduced recurrence, and served as an independent prognosticator for HCC patients. Furthermore, FOXP3 could potently suppress the proliferation and invasion of HCC cells in vitro and reduce tumor growth in vivo. However,Delta 3,4-FOXP3 showed a significant reduction in the tumor-inhibiting effect. The inhibition of FOXP3 on HCC aggressiveness was acted probably by enhancing the TGF-beta/Smad2/3 signaling pathway.Conclusion: Our findings suggest that FOXP3 suppresses tumor progression in HCC via TGF-beta/Smad2/3 signaling pathway, highlighting the role of FOXP3 as a prognostic factor and novel target for an optimal therapy against this fatal malignancy.
Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies

Wanyao Wang,Minglu Ding,Qiuhong Wang,Yidan Song,Keyuan Huo,Xiaojie Chen,Zihan Xiang,Lantao Liu

DOI: https://doi.org/10.3389/fimmu.2024.1404974

IF: 7.3

2024-06-12

Frontiers in Immunology

Abstract:Foxp3+ regulatory T cells (Foxp3+ Treg) play a role in regulating various types of tumors, but uncertainty still exists regarding the exact mechanism underlying Foxp3+ Treg activation in gastrointestinal malignancies. As of now, research has shown that Foxp3+ Treg expression, altered glucose metabolism, or a hypoxic tumor microenvironment all affect Foxp3+ Treg function in the bodies of tumor patients. Furthermore, it has been demonstrated that post-translational modifications are essential for mature Foxp3 to function properly. Additionally, a considerable number of non-coding RNAs (ncRNAs) have been implicated in the activation of the Foxp3 signaling pathway. These mechanisms regulating Foxp3 may one day serve as potential therapeutic targets for gastrointestinal malignancies. This review primarily focuses on the properties and capabilities of Foxp3 and Foxp3+Treg. It emphasizes the advancement of research on the regulatory mechanisms of Foxp3 in different malignant tumors of the digestive system, providing new insights for the exploration of anticancer treatments.

immunology
FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-β/Smad2/3 signaling pathway.

Jie-Yi Shi,Li-Jie Ma,Ji-Wei Zhang,Meng Duan,Zhen-Bin Ding,Liu-Xiao Yang,Ya Cao,Jian Zhou,Jia Fan,Xiaoming Zhang,Ying-Jun Zhao,Xiao-Ying Wang,Qiang Gao

DOI: https://doi.org/10.1186/s12885-017-3633-6

IF: 4.638

2017-01-01

BMC Cancer

Abstract:BACKGROUND:FOXP3 has been discovered to be expressed in tumor cells and participate in the regulation of tumor behavior. Herein, we investigated the clinical relevance and biological significance of FOXP3 expression in human hepatocellular carcinoma (HCC). METHODS:Expression profile of FOXP3 was analyzed using real-time RT-PCR, western blotting and immunofluorescence on HCC cell lines, and immunostaing of a tissue microarray containing of 240 primary HCC samples. The potential regulatory roles of FOXP3 were dissected by an integrated approach, combining biochemical assays, analysis of patient survival, genetic manipulation of HCC cell lines, mouse xenograft tumor models and chromatin immunoprecipitation (ChIP) sequencing. RESULTS:FOXP3 was constitutively expressed in HCC cells with the existence of splice variants (especially exon 3 and 4 deleted, Δ3,4-FOXP3). High expression of FOXP3 significantly correlated with low serum α-fetoprotein (AFP) level, absence of vascular invasion and early TNM stage. Survival analyses revealed that increased FOXP3 expression was significantly associated with better survival and reduced recurrence, and served as an independent prognosticator for HCC patients. Furthermore, FOXP3 could potently suppress the proliferation and invasion of HCC cells in vitro and reduce tumor growth in vivo. However, Δ3,4-FOXP3 showed a significant reduction in the tumor-inhibiting effect. The inhibition of FOXP3 on HCC aggressiveness was acted probably by enhancing the TGF-β/Smad2/3 signaling pathway. CONCLUSION:Our findings suggest that FOXP3 suppresses tumor progression in HCC via TGF-β/Smad2/3 signaling pathway, highlighting the role of FOXP3 as a prognostic factor and novel target for an optimal therapy against this fatal malignancy.

Role of FOXP3 in Tumor Immunity

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

The Role of FOXP3 on Tumor Metastasis and Its Interaction with Traditional Chinese Medicine

FOXP3: A Player of Immunogenetic Architecture in Lung Cancer

FOXN Transcription Factors: Regulation and Significant Role in Cancer

The regulation of immune tolerance by FOXP3

A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.

The emerging role of transcription factor FOXP3 in thyroid cancer

Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapy Value of FOXP3

FOXP3+ regulatory T cells and the immune escape in solid tumours

Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex.

FOXP3+ Tregs: Heterogeneous Phenotypes and Conflicting Impacts on Survival Outcomes in Patients with Colorectal Cancer

FOXP3 and Its Partners: Structural and Biochemical Insights into the Regulation of FOXP3 Activity

Molecular and biological role of the FOXP3 N-terminal domain in immune regulation by T regulatory/suppressor cells.

Abstract 4988: FOXP3, a Critical Mediator of Regulatory T-cell Function, is Expressed in Subsets of Myeloid Cells.

FOXP3 suppresses breast cancer metastasis through downregulation of CD44

Advance in the Study of CD4~+CD25~+FOXP3~+ Regulatory T Cell in Tumor Immune Evasion

What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?

FOXP3 is a HCC Suppressor Gene and Acts Through Regulating the TGF-β/Smad2/3 Signaling Pathway

Advances in Foxp3+ regulatory T cells (Foxp3+ Treg) and key factors in digestive malignancies

FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF-β/Smad2/3 signaling pathway.